Cargando…
Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major
In conditions requiring repeated blood transfusion or where iron metabolism is abnormal, heart failure may result from accumulation of iron in the heart (cardiac siderosis). Death due to heart failure from cardiac iron overload has accounted for considerable early mortality in β-thalassemia major. T...
Autores principales: | Baksi, A. John, Pennell, Dudley J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172003/ https://www.ncbi.nlm.nih.gov/pubmed/25295007 http://dx.doi.org/10.3389/fphar.2014.00217 |
Ejemplares similares
-
Regional siderosis: a new challenge for iron chelation therapy
por: Cabantchik, Zvi Ioav, et al.
Publicado: (2013) -
Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018) -
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
por: Tanner, Mark A, et al.
Publicado: (2008) -
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study
por: Berdoukas, Vasilios, et al.
Publicado: (2009) -
T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis
por: Alam, Mohammed H., et al.
Publicado: (2015)